Erratum; Multi-targeting by monotherapeutic antibacterials (Nature Reviews Drug Discovery (2007) vol. 6 (41-55) 10.1038/nrd2202);Multi-targeting by monotherapeutic antibacterials

Nature Reviews Drug Discovery

Volumn 6, Issue 1, 2007, Pages 41-55

  Silver, Lynn L ^a  

^a LL Silver Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CHLORAMPHENICOL; CUBIST; DALFOPRISTIN; DAPTOMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; ICLAPRIM; LINCOSAMIDE DERIVATIVE; MACROLIDE; METRONIDAZOLE; MONOBACTAM; NITROFURANTOIN; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBOSOME RNA; RIFAMPICIN; SULFAMETHOXAZOLE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; COMMERCIAL PHENOMENA; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW;

EID: 33845894155     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2263     Document Type: Erratum

References (160)

1. Loferer, H. Mining bacterial genomes for antimicrobial targets. Mol. Med. Today 6, 470-474 (2000).
2. McDevitt, D. & Rosenberg, M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9, 611-617 (2001).
3. Mills, S. D. When will the genomics investment pay off for antibacterial discovery? Biochem Pharmacol. 71, 1096-1102 (2006).
4. Pucci, M. J. Use of genomics to select antibacterial targets. Biochem. Pharmacol. 71, 1066-1072 (2006).
5. Barlow, M. & Hall, B. G. Origin and evolution of the AmpC β-lactamases of Citrobacter freundii. Antimicrob. Agents Chemother. 46, 1190-1198 (2002).
6. Silver, L. L. & Bostian, K. A. Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrob. Agents Chemother. 37, 377-383 (1993).
7. Spratt, B. G. Resistance to antibiotics mediated by target alterations. Science 264, 388-393 (1994).
8. Ng, E. Y., Trucksis, M. & Hooper, D. C. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40, 1881-1888 (1996).
9. Chopra, I. Protein synthesis as a target for antibacterial drugs: current status and future opportunities. Expert Opin. Investig. Drugs 7, 1237-1244 (1998).
10. Schmid, M. B. Crystallizing new approaches for antimicrobial drug discovery. Biochem. Pharmacol. 71, 1048-1056 (2006).
11. Nilsson, A. I., Berg, O. G., Aspevall, O., Kahlmeter, G. & Andersson, D. I. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47, 2850-2858 (2003).
12. Kim, D. H. et al. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 35, 4923-4928 (1996).
13. Du, W. et al. Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J. Bacteriol. 182, 4146-4152 (2000).
14. Martinez, J. L. & Baquero, F. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44, 1771-1777 (2000).
15. Wise, E. M. Jr. & Park, J. T. Penicillin: Its basic site of action as an inhibitor of a peptide cross-linking reaction in cell wall mucopeptide synthesis. Proc. Natl Acad. Sci. USA 54, 75-81 (1965).
16. Tipper, D. J. & Strominger, J. L. Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl Acad. Sci. USA 54, 1133-1141 (1965).
17. Izaki, K., Matsuhashi, M. & Strominger, J. L. Biosynthesis of the peptidoglycan of bacterial cell walls. XIII. Peptidoglycan transpeptidase and D-alanine carboxypeptidase: Penicillin-sensitive enzymatic reaction in strains of Escherichia coli. J. Biol. Chem. 243, 3180-3192 (1968).
18. Blumberg, P. M. & Strominger, J. L. Interaction of penicillin with the bacterial cell: Penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol. Rev. 38, 291-335 (1974).
19. Georgopapadakou, N. H. & Liu, F. Y. Penicillin-binding proteins in bacteria. Antimicrob. Agents Chemother. 18, 148-157 (1980).
20. Goffin, C. & Ghuysen, J.-M. Multimodular penicillin-binding proteins: An enigmatic family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. 62, 1079-1093 (1998).
21. Massova, I. & Mobashery, S. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob. Agents Chemother. 42, 1-17 (1998).
22. Spratt, B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc. Natl Acad. Sci. USA 72, 2999-3003 (1975).
23. Curtis, N. A., Orr, D., Ross, G. W. & Boulton, M. G. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob. Agents Chemother. 16, 533-539 (1979).
24. Denome, S. A., Elf, P. K., Henderson, T. A., Nelson, D. E. & Young, K. D. Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: Viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol. 181, 3981-3993 (1999).
25. Wada, A. & Watanabe, H. Penicillin-binding protein 1 of Staphylococcus aureus is essential for growth. J. Bacteriol. 180, 2759-2765 (1998).
26. Pinho, M. G., Filipe, S. R., de Lencastre, H. & Tomasz, A. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J. Bacteriol. 183, 6525-6531 (2001).
27. Pinho, M. G., de Lencastre, H. & Tomasz, A. Cloning, characterization, and inactivation of the gene pbpC, encoding penicillin-binding protein 3 of Staphylococcus aureus. J. Bacteriol. 182, 1074-1079 (2000).
28. Curtis, N., Hayes, M., Wyke, A. & Ward, J. A mutant of Staphylococcus aureus H lacking penicillin-binding protein 4 and transpeptidase activity in vitro. FEMS Microbiol. Lett. 9, 263-266 (1980).
29. Beise, F., Labischinski, H. & Giesbrecht, P. Selective inhibition of penicillin-binding proteins and its effects on growth and architecture of Staphylococcus aureus. FEMS Microbiol. Lett. 55, 195-202 (1988).
30. Spratt, B. G., Bowler, L. D., Zhang, Q. Y., Zhou, J. & Smith, J. M. Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J. Mol. Evol. 34, 115-125 (1992).
31. Dowson, C. G., Coffey, T. J., Kell, C. & Whiley, R. A. Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae. Mol. Microbiol. 9, 635-643 (1993).
32. Feil, E. J., Enright, M. C. & Spratt, B. G. Estimating the relative contributions of mutation and recombination to clonal diversification: A comparison between Neisseria meningitidis and Streptococcus pneumoniae. Res. Microbiol. 151, 465-469 (2000).
33. Wu, S. W., de Lencastre, H. & Tomasz, A. Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. J. Bacteriol. 183, 2417-2424 (2001).
34. Fuda, C., Suvorov, M., Vakulenko, S. B. & Mobashery, S. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279, 40802-40806 (2004).
35. De Stasio, E. A., Moazed, D., Noller, H. F. & Dahlberg, A. E. Mutations in 16S ribosomal RNA disrupt antibiotic-RNA interactions. EMBO J 8, 1213-1216 (1989).
36. Carter, A. P. et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340-348 (2000).
37. Hansen, J. L. et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol. Cell 10, 117-128 (2002).
38. Sutcliffe, J. The search for new antibiotics targeting the 50S ribozyme. Am. Soc. Microbiol. News 70, 513-529 (2004).
39. Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375-382 (1994).
40. Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H. & Vester, B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: Methylation of 23S ribosomal RNA at A2503. Mol. Microbiol. 57, 1064-1073 (2005).
41. Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S. & Vester, B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother. 50, 2500-2505 (2006).
42. Kehrenberg, C. & Schwarz, S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50, 1156-1163 (2006).
43. Mankin, A., Toh, S., Xiong, L., Lolans, K. & Quinn, J. New mechanism of linezolid resistance in MRSA based on posttranscriptional modification of ribosomal RNA. Intersci. Conf. Antimicrob. Agents Chemother. 46, C1-942 (2006).
44. Cundliffe, E. On the nature of antibiotic binding sites in ribosomes. Biochimie 69, 863-869 (1987).
45. Klappenbach, J. A., Saxman, P. R., Cole, J. R. & Schmidt, T. M. rrndb: the ribosomal RNA operon copy number database. Nucl. Acids Res. 29, 181-184 (2001).
46. Sigmund, C. D., Ettayebi, M. & Morgan, E. A. Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res. 12, 4653-4663 (1984).
47. Bercovier, H., Kafri, O. & Sela, S. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem. Biophys. Res. Commun. 136, 1136-1141 (1986).
48. Alangaden, G. J. et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1295-1297 (1998).
49. Meier, A. et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: Observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174, 354-360 (1996).
50. Prystowsky, J. et al. Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45, 2154-2156 (2001).
51. Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A. & Rice, L. B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46, 3334-3336 (2002).
52. Tait-Kamradt, A. et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother. 44, 3395-3401 (2000).
53. Doktor, S. Z., Shortridge, V. D., Beyer, J. M. & Flamm, R. K. Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations. Diagn. Microbiol. Infect. Dis. 49, 47-52 (2004).
54. Farrell, D. J. et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother. 47, 1777-1783 (2003).
55. Tait-Kamradt, A. et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44, 2118-2125 (2000).
56. Pereyre, S. et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 48, 460-465 (2004).
57. Chittum, H. S. & Champney, W. S. Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli. J. Bacteriol. 176, 6192-6198 (1994).
58. Canu, A. et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46, 125-131 (2002).
59. Gregory, S. T. & Dahlberg, A. E. Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA. J. Mol. Biol. 289, 827-834 (1999).
60. Prunier, A. L. et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 187, 1709-1716 (2003).
61. Prunier, A.-L., Malbruny, B., Tande, D., Picard, B. & Leclercq, R. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob. Agents Chemother. 46, 3054-3056 (2002).
62. Gellert, M., Mizuuchi, K., O'Dea, M. H. & Nash, H. A. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc. Natl Acad. Sci. USA 73, 3872-3876 (1976).
63. Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H. & Brundage, R. P. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 91, 1063-1065 (1962).
64. Goss, W. A., Deitz, W. H. & Cook, T. M. Mechanism of action of nalidixic acid on Escherichia coli. J. Bacteriol. 88, 1112-1118 (1964).
65. Goss, W. A., Deitz, W. H. & Cook, T. M. Mechanism of action of nalidixic acid on Escherichia coli. II. Inhibition of deoxyribonucleic acid synthesis. J. Bacteriol. 89, 1068-1074 (1965).
66. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T. & Tomizawa, J.-I. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity. Proc. Natl Acad. Sci. USA 74, 4772-4776 (1977).
67. Sugino, A., Peebles, C. L., Kreuzer, K. N. & Cozzarelli, N. R. Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl Acad. Sci. USA 74, 4767-4771 (1977).
68. Ferrero, L. et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones. Mol. Microbiol. 13, 641-653 (1994).
69. Chen, C. R., Malik, M., Snyder, M. & Drlica, K. DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage. J. Mol. Biol. 258, 627-637 (1996).
70. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl Acad. Sci. USA 92, 11801-11805 (1995).
71. Pan, X. S. & Fisher, L. M. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178, 4 060-4069 (1996).
72. Fukuda, H. & Hiramatsu, K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43, 410-412 (1999).
73. Takei, M., Fukuda, H., Kishii, R. & Hosaka, M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45, 3544-3547 (2001).
74. Hooper, D. C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31 (Suppl 2), S24-S28 (2000).
75. Ferrero, L., Cameron, B. & Crouzet, J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39, 1554-1558 (1995).
76. Strahilevitz, J. & Hooper, D. C. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob. Agents Chemother. 49, 1949-1956 (2005).
77. Boos, M. et al. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45, 938-942 (2001).
78. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33 (Suppl 3), S147-S156 (2001).
79. Drlica, K. A strategy for fighting antibiotic resistance. Am. Soc. Microbiol. News 67, 27-33 (2001).
80. Reynolds, P. E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8, 943-950 (1989).
81. Ge, M. et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-ala-Dala. Science 284, 507-511 (1999).
82. Leclercq, R., Derlot, E., Weber, M., Duval, J. & Courvalin, P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 33, 10-15 (1989).
83. Marshall, C. G., Lessard, I. A. D., Park, I. S. & Wright, G. D. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. Antimicrob. Agents Chemother. 42, 2215-2220 (1998).
84. Cudic, P. et al. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: Minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl Acad. Sci. USA 99, 7384-7389 (2002).
85. Farver, D. K., Hedge, D. D. & Lee, S. C. Ramoplanin: A lipoglycodepsipeptide antibiotic. Ann. Pharmacother. 39, 863-868 (2005).
86. Bonev, B. B., Breukink, E., Swiezewska, E., De Kruijff, B. E. N. & Watts, A. Targeting extracellular pyrophosphates underpins the high selectivity of nisin. FASEB J. 18, 1862-1869 (2004).
87. Weiss, W. J., Murphy, T., Lenoy, E. & Young, M. In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models. Antimicrob. Agents Chemother. 48, 1708-1712 (2004).
88. Silverman, J. A., Perlmutter, N. G. & Shapiro, H. M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538-2544 (2003).
89. Friedman, L., Alder, J. D. & Silverman, J. A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 2137-2145 (2006).
90. Peschel, A. et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193, 1067-1076 (2001).
91. Cui, L., Tominaga, E., Neoh, H.-m. & Hiramatsu, K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 1079-1082 (2006).
92. Ratcliffe, R. W. et al. Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786, 392. Bioorg. Med. Chem. Lett. 9, 679-684 (1999).
93. Nagano, R. et al. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41, 2278-2281 (1997).
94. Kurazono, M. et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 48, 2831-2837 (2004).
95. Malouin, F. et al. RWJ-54428 (MC-02, 479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal β-lactamases. Antimicrob. Agents Chemother. 47, 658-664 (2003).
96. Chambers, H. F. Ceftobiprole: In-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12, 17-22 (2006).
97. Page, M. G. Anti-MRSA β-lactams in development. Curr. Opin. Pharmacol. 6, 480-485 (2006).
98. Iizawa, Y. et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother. 10, 146-156 (2004).
99. Koga, T. et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. 49, 3239-3250 (2005).
100. Chopra, I. & Roberts, M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232-260 (2001).
101. Olson, M. W. et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents Chemother. 50, 2156-2166 (2006).
102. Hirata, T., Saito, A., Nishino, K., Tamura, N. & Yamaguchi, A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob. Agents Chemother. 48, 2179-2184 (2004).
103. Stein, G. E. & Craig, W. A. Tigecycline: A critical analysis. Clin. Infect. Dis. 43, 518-524 (2006).
104. Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E. & Bradford, P. A. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47, 972-978 (2003).
105. Bowser, T. et al. PTK0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant Gram-positive bacteria. Intersci. Conf. Antimicrob. Agents Chemother. 43, F-755 (2003).
106. Silver, L. L. Antibacterial drug discovery and development - SRI's 11th annual summit. Antibacterial trends and current research. IDrugs 9, 394-397 (2006).
107. Bonnefoy, A., Girard, A. M., Agouridas, C. & Chantot, J. F. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother. 40, 85-90 (1997).
108. Douthwaite, S. Structure-activity relationships of ketolides vs. macrolides. Clin. Microbiol. Infect. 7, 11-17 (2001).
109. Hansen, L. H., Mauvais, P. & Douthwaite, S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol. 31, 623-631 (1999).
110. Berisio, R. et al. Structural insight into the antibiotic action of telithromycin against resistant mutants. J. Bacteriol. 185, 4276-4279 (2003).
111. Tu, D., Blaha, G., Moore, P. B. & Steitz, T. A. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 121, 257-270 (2005).
112. Franceschi, F. & Duffy, E. M. Structure-based drug design meets the ribosome. Biochem. Pharmacol. 71, 1016-1025 (2006).
113. Haddad, J. et al. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J. Am. Chem. Soc. 124, 3229-3237 (2002).
114. Russell, R. J. M., Murray, J. B., Lentzen, G., Haddad, J. & Mobashery, S. The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J. Am. Chem. Soc. 125, 3410-3411 (2003).
115. Skripkin, E. et al. Designer oxazolidinones bind to the 50S peptidyl-transferase region and can overcome ribosome-based linezolid resistance. Intersci. Conf. Antimicrob. Chemother. 45, F-1255 (2005).
116. Hawser, S. P. Antibacterial drug discovery and development - SRI's 11th annual summit. IDrugs 9, 390-393 (2006).
117. Coleman, K. & Jones, M. In vitro activity of a novel isoxazolino oxazolidinone against recent aerobic clinical isolates, including linezolid-resistant strains. Intersci. Conf. Antimicrobiol. Agents Chemother. 45, F-1238 (2005).
118. Gellert, M., O'Dea, M. H., Itoh, T. & Tomizawa, J. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc. Natl Acad. Sci. USA 73, 4474-4478 (1976).
119. Orr, E., Fairweather, N. F., Holland, I. B. & Pritchard, R. H. Isolation and characterisation of a strain carrying a conditional lethal mutation in the cou gene of Escherichia coli K12. Mol. Gen. Genet. 177, 103-112 (1979).
120. Hooper, D. C., Wolfson, J. S., McHugh, G. L., Winters, M. B. & Swartz, M. N. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth. Antimicrob. Agents Chemother. 22, 662-671 (1982).
121. Maxwell, A. The interaction between coumarin drugs and DNA gyrase. Mol. Microbiol. 9, 681-686 (1993).
122. Fujimoto-Nakamura, M., Ito, H., Oyamada, Y., Nishino, T. & Yamagishi, J.-i. Accumulation of mutations in both gyrB and parE genes is associated with high-Level resistance to novobiocin in Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 3810-3815 (2005).
123. Kirby, W. M., Hudson, D. G. & Noyes, W. D. Clinical and laboratory studies of novobiocin, a new antibiotic. AMA Arch. Intern. Med. 98, 1-7 (1956).
124. Bellon, S. et al. Crystal structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 kilodaltons): A single residue dictates differences in novobiocin potency against Topoisomerase IV and DNA Gyrase. Antimicrob. Agents Chemother. 48, 1856-1864 (2004).
125. Grillot, A. et al. A new class of dual targeting Iinhibitors of GyrB and ParE. Intersci. Conf. Antibacteriol. Agents. Chemother. 44, F-1951 (2004).
126. Mani, N. et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase Inhibitors of the aminobenzimidazole Class. Antimicrob. Agents Chemother. 50, 1228-1237 (2006).
127. Mackenzie, J. M., Neville, M. M., Wright, G. E. & Brown, N. C. Hydroxyphenylazopyrimidines: Characterization of the active forms and their inhibitory action on a DNA polymerase from Bacillus subtilis. Proc. Natl Acad. Sci. USA 70, 512-516 (1973).
128. Gass, K. B., Low, R. L. & Cozzarelli, N. R. Inhibition of a DNA polymerase from Bacillus subtilis by hydroxyph enylazopyrimidines Proc. Natl Acad. Sci. USA 70, 103-107 (1973).
129. Daly, J. S. et al. In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of Gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2217-2221 (2000).
130. Butler, M. M. et al. Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N3-hydroxybutyl 6-(3′-ethyl-4′-methylanilino) uracil. Antimicrob. Agents Chemother. 46, 3770-3775 (2002).
131. Zhi, C. et al. Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils. J. Med. Chem. 48, 7063-7074 (2005).
132. Kuhl, A. et al. Biological characterization of novel inhibitors of the Gram-positive DNA polymerase IIIC enzyme. Antimicrob. Agents Chemother. 49, 987-995 (2005).
133. Wright, G. E. et al. Active site directed inhibitors of replication-specific bacterial DNA polymerases. Bioorg. Med. Chem. Lett. 15, 729-732 (2005).
134. Georgopapadakou, N. H. & Bertasso, A. Mechanisms of action of cephalosporin 3′-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob. Agents Chemother. 37, 559-565 (1993).
135. Pace, J., Bertasso, A. & Georgopapadakou, N. H. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424. Antimicrob. Agents Chemother. 35, 910-915 (1991).
136. Pfaller, M. A., Barry, A. L. & Fuchs, P. C. RO 23-9424, a new cephalosporin 3′-quinolone: In-vitro antimicrobial activity and tentative disc diffusion interpretive criteria. J. Antimicrob. Chemother. 31, 81-88 (1993).
137. Hubschwerlen, C. et al. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: Influence of the central spacer on the antibacterial activity and the mode of action. Bioorg. Med. Chem. Lett. 13, 4229-4233 (2003).
138. Locher, H. et al. Antibacterial characterization and mode of action of new oxazolidinone-quinolone hybrids. Interesci. Conf. Antimicrob. Agents Chemother. 43, F-2145 (2003).
139. Ding, C. et al. Rifamycin imino derivatives effective against drug-resistant microbes. Cumbre, Inc. US Patent US2005/0209210 A1 (2005).
140. Ding, C. et al. Rifamycin derivatives, their preparations and pharmaceutical compositions. US Patent US2006/0019986 (2006).
141. Zhi, C. et al. Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J. Med. Chem. 49, 1455-1465 (2006).
142. Griffin, J. & Pace, J. Multivalent macrolide antibiotics. Theravance, Inc. US Patent US 6566509 B1 (2003).
143. Pace, J. L. & Yang, G. Glycopeptides: Update on an old successful antibiotic class. Biochem. Pharmacol. 71, 968-980 (2006).
144. Theravance Press Release. Theravance and Astellas add Japan to collaboration on telavancin, investigational antibiotic for serious infections. (July 18, 2006) (cited November 2006).
145. Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005).
146. McKay, G. et al. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci. Intersci. Conf. Antimicrob. Agents Chemother. 46, C1-682 (2006).
147. Replidyne Inc. Replidyne commences clinical trials for REP8839. (July 18, 2006) (cited November 2006).
148. Rattan, A., Kalia, A. & Ahmad, N. Multidrug-resistant Mycobacterium tuberculosis: Molecular perspectives. Emerg. Infect. Dis. 4, 195-209 (1998).
149. Ramaswamy, S. & Musser, J. M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79, 3-29 (1998).
150. Rengarajan, J. et al. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol. 53, 275-282 (2004).
151. Johansen, S. K., Maus, C. E., Plikaytis, B. B. & Douthwaite, S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′-Omethylations in 16S and 23S rRNAs. Mol. Cell 23, 173-182 (2006).
152. Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Med. 2, 662-667 (1996).
153. Vannelli, T. A., Dykman, A. & Ortiz de Montellano, P. R. The antituberculosis drug ethionamide Is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277, 12824-12829 (2002).
154. Gillespie, S. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob. Agents Chemother. 46, 267-274 (2002).
155. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
156. NJMS Global Tuberculosis Institute. History of TB. (cited November 2006).
157. Gemmell, C. G. et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57, 589-608 (2006).
158. Shlaes, D. et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25, 584-599 (1997).
159. Schneider, P., Hawser, S. & Islam, K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13, 4217-4221 (2003).
160. Silver, L. & Bostian, K. Screening of natural products for antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 9, 455-461 (1990).